by Pete Celano | May 11, 2025 | Uncategorized
The New England Journal of Medicine recently published a study titled “Efruxifermin in Compensated Liver Cirrhosis Caused by MASH” on May 7, 2025. This phase 3 clinical trial evaluated the efficacy and safety of efruxifermin, a fibroblast growth factor 21...
by Pete Celano | May 7, 2025 | Uncategorized
Bold move by an innovative hospital system. New York, NY May 07, 2025 “To advance the understanding and treatment of liver disease by pursuing innovative, transformative basic and translational research, leaders at the Icahn School of Medicine at Mount Sinai...
by Pete Celano | May 1, 2025 | Uncategorized
If you know about Liver Disease – Hepatitis, MASLD/MASH, ALD, PBC – it’s likely because of what we call here at LiverRight “The Tremendous Twenty.”There are 20 passionate, proud & powerful ADVOCACY organizations in the USA and around...
by Pete Celano | Apr 27, 2025 | Uncategorized
As reported in: Per a new October 2024 study titled “Hepatitis Delta Virus Testing, Prevalence, and Liver-Related Outcomes Among US Veterans With Chronic Hepatitis B,” only 1 in 6 US veterans with chronic hepatitis B (CHB) is also tested for hepatitis D...
by Pete Celano | Apr 25, 2025 | Uncategorized
If you know about Liver Disease – Hepatitis, MASLD/MASH, ALD, PBC – it’s likely because of what we call here at LiverRight “The Tremendous Twenty.”There are 20 passionate, proud & powerful ADVOCACY organizations in the USA and around...
